Plus, news about Newron and SynOx:
Daré Bioscience inks royalty deal with XOMA: The company received $22 million, which is expected to help progress a pair of women’s health therapies through Phase 3. Dare’s stock $DARE was up about 28% after announcing the agreement. — Jaimy Lee
Qlaris Bio secures $24M in Series B: The proceeds will support the continued development of the biotech’s Phase 2 asset, QLS‑111, which is designed to lower intraocular pressure in patients with open-angle glaucoma and ocular hypertension. The fundraise was co-led by Canaan and New Leaf Venture Partners. — Ayisha Sharma
Newron touts positive Ph2/3 schizophrenia data: The Milan-based biotech said evenamide hit the trial’s primary endpoint of improvement in the Positive and Negative Syndrome Scale Total Score versus placebo at four weeks (p-value=0.006). One-quarter of evenamide patients experienced at least one adverse event versus 25.8% of placebo patients. — Ayisha Sharma
SynOx enters $35M loan facility with Hercules Capital: The debt financing is expected to fund “additional clinical work and activities” as the Irish biotech starts a Phase 3 trial of its lead candidate, emactuzumab, in tenosynovial giant cell tumors. The loan facility will be spread across four tranches. — Ayisha Sharma